Loading...
XHKG2196
Market cap8.50bUSD
Dec 23, Last price  
13.88HKD
1D
0.29%
1Q
9.29%
Jan 2017
-41.56%
Name

Shanghai Fosun Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XHKG:2196 chart
P/E
13.23
P/S
0.76
EPS
0.99
Div Yield, %
7.30%
Shrs. gr., 5y
1.16%
Rev. gr., 5y
10.69%
Revenues
41.40b
-5.81%
2,425,435,9182,988,526,8243,102,002,4043,693,301,6783,773,234,2203,872,256,3264,555,421,6866,485,540,8007,340,782,7219,996,409,00912,025,532,04512,608,648,31414,628,820,44318,533,555,41824,918,273,56128,585,152,03330,306,981,26439,005,086,60243,951,546,89541,399,539,588
Net income
2.39b
-36.04%
215,333,391159,030,715259,157,973625,781,242690,856,5412,498,201,836863,653,9061,165,607,6291,563,916,4412,027,057,7362,112,869,4672,460,093,5832,805,837,0713,124,499,5492,707,923,4183,321,617,5663,662,812,9374,728,710,5273,730,804,5822,386,265,813
CFO
4.36b
+3.45%
205,100,591188,346,350184,914,259131,477,131233,041,247261,867,525203,362,919316,649,971665,517,0201,011,633,3741,200,214,1911,621,027,8752,110,039,2652,580,225,7752,950,105,2133,222,412,5712,579,774,3493,948,747,0094,217,570,8924,363,275,634
Dividend
Jul 26, 20240.3 HKD/sh

Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
URL
https://www.fosunpharma.com/
IPO date
Aug 07, 1998
Employees
38,591
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
41,399,540
-5.81%
43,951,547
12.68%
39,005,087
28.70%
Cost of revenue
33,314,223
37,631,021
34,007,753
Unusual Expense (Income)
NOPBT
8,085,317
6,320,525
4,997,334
NOPBT Margin
19.53%
14.38%
12.81%
Operating Taxes
369,504
626,917
1,066,400
Tax Rate
4.57%
9.92%
21.34%
NOPAT
7,715,812
5,693,608
3,930,933
Net income
2,386,266
-36.04%
3,730,805
-21.10%
4,728,711
29.10%
Dividends
(2,455,170)
(1,435,465)
(1,102,997)
Dividend yield
3.66%
1.56%
0.88%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
14,728,454
17,402,869
14,547,617
Long-term debt
17,604,102
13,589,854
10,345,790
Deferred revenue
632,433
512,806
Other long-term liabilities
7,541,248
2,916,694
2,268,299
Net debt
(8,809,372)
(10,797,642)
(9,334,868)
Cash flow
Cash from operating activities
4,363,276
4,217,571
3,948,747
CAPEX
(5,336,705)
Cash from investing activities
(4,777,859)
Cash from financing activities
(1,326,740)
4,428,475
FCF
2,287,458
1,848,390
5,729,000
Balance
Cash
15,582,087
17,169,846
14,549,226
Long term investments
25,559,840
24,620,519
19,679,049
Excess cash
39,071,951
39,592,787
32,278,021
Stockholders' equity
36,846,319
38,519,031
37,197,379
Invested Capital
57,594,157
48,456,900
42,396,174
ROIC
14.55%
12.53%
9.77%
ROCE
8.56%
7.00%
6.42%
EV
Common stock shares outstanding
2,681,198
2,607,385
2,562,899
Price
25.03
-28.97%
35.24
-27.99%
48.94
-9.35%
Market cap
67,110,375
-26.96%
91,884,247
-26.74%
125,428,255
-9.35%
EV
69,232,502
90,613,057
125,277,002
EBITDA
11,203,995
8,656,437
6,831,714
EV/EBITDA
6.18
10.47
18.34
Interest
1,324,831
963,807
822,534
Interest/NOPBT
16.39%
15.25%
16.46%